Our History

Vermillion develops a partnership with Johns Hopkins University on the development of novel biomarkers to detect ovarian, breast and prostate cancers.

Vermillion receives a Department of Defense Idea Development Grant that funds the discovery of biomarkers that later lead to the development of the first ovarian cancer diagnostic tool.

Quest and Vermillion enter into a joint agreement to accelerate the development and commercialization of Ova1

Vermillion completes an initial public offering of its stock on the Nasdaq stock exchange, trading under the symbol VRML

Ova1 is the first- ever proteomic in vitro diagnostic multivariate index assay to be approved by the FDA for clinical use for the assessment of ovarian cancer malignancy risk in women with pelvic masses when a surgical response is planned. Ova1 has a Negative Predictive Value (NPV) of 91%.

Overa – Vermillion’s second generation blood-based ovarian cancer risk assessment with an improved Positive Predictive Value (PPV) of 79% is approved by the FDA.

https://pubmed.ncbi.nlm.nih.gov/26970494/

Vermillion Inc Announces OVA1® (MIA) and OVERA® (MIA2G) Study and Coverage by Clalit Health Services in Israel

First generation of OVAWatch published.

https://pubmed.ncbi.nlm.nih.gov/31570013/

Ova1Plus launched to combine the sensitivity and specificity of Ova1 and Overa.

Vermillion, Inc. becomes Aspira Women’s Health, Inc. and begins trading under the ticker symbol AWH.

Aspira rings the closing bell at Nasdaq in recognition of Ovarian Cancer Awareness Month

>Watch Here

Aspira launches a distribution and co-marketing relationship with BioReference Laboratories for Ova1Plus.

OvaWatch, the first of its kind lab developed test, is launched. With a Negative Predictive Value (NPV) of 99%, allowing healthcare providers to confidently rule-out ovarian cancer in all women with pelvic masses as part of the initial clinical assessment.